Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus
The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
1. A method of treating a patient diagnosed with an autoimmune disorder having the symptom of accumulation of tingible body macrophages comprising:
administering to said patient an effective amount of an agent,
wherein the disorder is selected from the group consisting of systemic lupus erythematosus, drug-induced lupus, neonatal lupus, cutaneous lupus, and rheumatoid arthritis,
wherein the agent comprises a peptide comprising an amino acid sequence selected from the group consisting of:
(a) an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO: 1;
(b) N-terminal truncations of (a); and
(c) C-terminal truncations of (a) or (b);
and wherein the agent has LPLA2 enzymatic activity.
2. The method of claim 1 wherein, the autoimmune disorder comprises systemic lupus erythematosus.
3. The method of claim 1 , wherein the autoimmune disorder comprises drug-induced lupus.
4. The method of claim 1 , wherein said agent is a mammalian LPLA2 enzyme.
5. The method of claim 1 , wherein said agent is a human LPLA2 enzyme.
6. The method of claim 4 , wherein said LPLA2 enzyme further comprises mannose or mannose-6-phosphate attached to the enzyme.
7. The method of claim 1 , wherein said agent comprises the amino acid sequence of SEQ ID NO: 1, or a fragment of at least 150 consecutive amino acids of SEQ ID NO: 1 that includes the LPLA2 catalytic domain of SEQ ID NO:1, said fragment having LPLA2 enzymatic activity.
8. The method of claim 5 , wherein said human LPLA2 enzyme further comprises a cysteine bond corresponding to the cysteine bond between the Cys at position 65 and the Cys at position 89 of SEQ ID NO: 1.
9. The method of claim 5 , wherein said human LPLA2 enzyme comprises an amino acid sequence having at least 95% identity to the amino acid sequence of a fragment of SEQ ID NO: 1 that is at least 75 residues in length and that comprises amino acids 196-200 of SEQ ID NO: 1.
10. The method of claim 1 , wherein said agent comprises mannose or mannose-6-phosphate attached to the peptide.
11. The method of claim 5 , further comprising mannose or mannose-6-phosphate attached to the human LPLA2 enzyme.
12. The method of claim 5 , wherein the human LPLA2 enzyme includes amino acids 34-412 of SEQ ID NO: 1.
13. A method of treating a patient diagnosed with lupus erythematosus, drug-induced lupus, neonatal lupus, cutaneous lupus, or rheumatoid arthritis, the method comprising:
administering to said patient an effective amount of an agent that has LPLA2 enzymatic activity and that comprises a peptide comprising an amino acid sequence selected from the group consisting of:
(a) enzymatically active human LPLA2 having an amino acid sequence of SEQ ID NO: 1;
(b) variants of (a) that differ from (a) at 15 or fewer amino acid residues;
(c) N-terminal truncations of (a) or (b); and
(d) C- terminal truncations of (a) - (c).
14. The method of claim 13 , wherein the peptide includes amino acids 34-412 of SEQ ID NO: 1.
15. The method of claim 14 , wherein said agent further comprises mannose or mannose-6-phosphate attached to the peptide.
16. The method of claim 13 , wherein the agent includes the N-glycosylation site consensus motifs corresponding to positions 99-101, 273-275, 289-291, and 398-400 of SEQ ID NO: 1.
17. The method of claim 16 , wherein said agent further includes mannose or mannose-6-phosphate attached to the peptide.
18. The method of claim 17 , wherein the agent further comprises a cysteine bond corresponding to the cysteine bond between the Cys at position 65 and the Cys at position 89 of SEQ ID NO: 1.
19. The method of claim 1 that comprises administering to the patient a composition that comprises the agent and a pharmaceutically acceptable excipient or carrier.
20. The method of claim 13 that comprises administering to the patient a composition that comprises the agent and a pharmaceutically acceptable excipient or carrier.